Antivirals (Non-HIV)

USMLE Step 1 trap: Misses that acyclovir's first phosphorylation step requires viral thymidine kinase, explaining its selective toxicity. Acyclovir is first phosphorylated by viral thymidine kinase (in HSV/VZV-infected cells), then further phosphorylated by host kinases to the active triphosphate form, conferring selectivity for infected cells.

Non-HIV antivirals are a high-yield pharmacology topic that trips up a lot of students because the drugs look similar on the surface but differ in critical ways — activation pathways, viral targets, and toxicity profiles. USMLE Step 1 loves to exploit those differences. The core drugs to own are acyclovir, ganciclovir, foscarnet, cidofovir, oseltamivir, and the HCV direct-acting antivirals (DAAs). Each has a specific mechanism, and the exam will test whether you actually understand how they work — not just what virus they treat.

The biggest traps here cluster around selectivity and activation. Acyclovir's genius is that it requires viral thymidine kinase for its first phosphorylation step — meaning it's only activated in infected cells. Students who miss this think host kinases do all the work, which leads to wrong answers about why acyclovir doesn't work for CMV (CMV lacks the right viral kinase). That single concept explains acyclovir's safety profile, its CMV limitation, and why resistance emerges from kinase mutations. USMLE Step 1 will test all three angles.

For influenza and hepatitis, the exam tests current management, and outdated knowledge will cost you. Amantadine/rimantadine only cover influenza A — not B. HCV treatment has moved entirely to DAA regimens (sofosbuvir-based); interferon is history. HBV uses tenofovir or entecavir. Questions in this area often come in clinical vignettes where you have to select the right drug class or identify why a treatment failed, so understanding mechanism is more useful than memorizing drug names in isolation.

From real student decks

86%have cards covering this topic

78%have mature cards

2.5median lapses in 14 days

One of the more frequently lapsed topics in Microbiology — most students have the cards but struggle to retain them.

Common misconceptions

Common mistake

Wrong: Acyclovir is activated by host cell kinases.

Right: Acyclovir is first phosphorylated by viral thymidine kinase (in HSV/VZV-infected cells), then further phosphorylated by host kinases to the active triphosphate form, conferring selectivity for infected cells.

Acyclovir is a prodrug that depends on viral thymidine kinase (encoded by HSV or VZV) to add the first phosphate group — host kinases can't do this step. Only after that initial viral kinase phosphorylation do host kinases complete the job, producing the active triphosphate. This two-step requirement is precisely why acyclovir is so selective: uninfected cells can't activate it, and infected cells that express viral TK get hit hardest.

Common mistake

Gap: Misses the mechanism of acyclovir resistance and the alternative agents used for resistant HSV

Acyclovir resistance in HSV most commonly results from mutation in viral thymidine kinase (preventing drug activation); resistant cases are treated with foscarnet or cidofovir, which do not require viral kinase activation.

When HSV mutates its thymidine kinase gene (most common resistance mechanism), acyclovir can no longer be activated in infected cells — the drug just sits there useless. Foscarnet and cidofovir are the go-to alternatives because they bypass viral kinase activation entirely: foscarnet directly inhibits viral DNA polymerase, and cidofovir is activated by host kinases alone. If a question tells you an immunocompromised patient has acyclovir-resistant HSV, the answer is foscarnet.

Common mistake

Wrong: Acyclovir is the drug of choice for CMV infections.

Right: Ganciclovir (or valganciclovir) is used for CMV; acyclovir has poor activity against CMV because CMV lacks the viral thymidine kinase needed for acyclovir activation.

CMV does not encode the same thymidine kinase that HSV/VZV use, so acyclovir never gets its critical first phosphorylation in CMV-infected cells — it has essentially no clinically useful activity against CMV. Ganciclovir is activated by a CMV-encoded kinase (UL97 phosphotransferase), making it the correct choice. Confusing these two is one of the most tested antiviral mistakes on USMLE Step 1.

Common mistake

Wrong: Amantadine is effective against both influenza A and B.

Right: Amantadine/rimantadine block the M2 ion channel and are active only against influenza A; oseltamivir and zanamivir (neuraminidase inhibitors) are active against both influenza A and B.

Amantadine and rimantadine work by blocking the M2 ion channel, which is a protein only expressed by influenza A — influenza B simply doesn't have M2, so these drugs are structurally irrelevant against it. Oseltamivir and zanamivir inhibit neuraminidase, an enzyme present in both influenza A and B, giving them broader coverage. In practice, widespread M2 resistance has made amantadine/rimantadine clinically obsolete even for influenza A.

Common mistake

Gap: Relies on outdated interferon-based HCV treatment rather than current direct-acting antiviral regimens

Modern HCV treatment uses direct-acting antivirals (DAAs) targeting NS3/4A protease, NS5A, and NS5B polymerase (e.g., sofosbuvir/ledipasvir), achieving >95% cure rates; interferon-based regimens are largely obsolete.

Interferon-based HCV regimens had poor cure rates, major side effects, and are no longer standard of care — don't anchor on them. Current DAAs target three viral proteins: NS3/4A serine protease (e.g., simeprevir), NS5A replication complex (e.g., ledipasvir), and NS5B RNA-dependent RNA polymerase (e.g., sofosbuvir). Combinations like sofosbuvir/ledipasvir achieve >95% sustained virologic response. The exam expects you to know the drug classes and their targets, not just that 'we use DAAs now.'

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Explain how acyclovir is activated in HSV/VZV-infected cells, compare it to ganciclovir's activation (relevant for CMV), and identify the toxicity profiles that differentiate these drugs clinically.
Select the appropriate antiviral for influenza A vs. B, explain why amantadine fails against influenza B, and describe the current standard-of-care regimens for HCV and HBV including the drug classes and their molecular targets.

Can you avoid these mistakes?

A patient with acyclovir-resistant HSV encephalitis needs treatment. Which drug would you choose, and why doesn't it have the same resistance problem as acyclovir?

You're asked to treat a CMV retinitis in an AIDS patient. Why is acyclovir the wrong choice, and what is the mechanism of the correct drug's activation?

An elderly patient presents with influenza B. A colleague suggests amantadine. What's wrong with that plan, and what is the correct drug class to use instead?

A patient with chronic HCV genotype 1 is asking about treatment options. What is the current standard of care, and what viral enzymes do the key drug components target?

Antivirals (Non-HIV)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics